Syndax Pharmaceuticals SNDX Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Jazz PharmaceuticalsJAZZ

-$51.9M-25.4%

SELLAS Life Sciences Group, Inc.SLS

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.77B+95.0%

Enterprise value$1.99B+84.0%

P/S8.1×-12.6×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's increase (decrease) in prepaid expense and other assets?: Syndax Pharmaceuticals (SNDX) reported increase (decrease) in prepaid expense and other assets of -$7.84M in Q1 2026.
How has Syndax Pharmaceuticals's increase (decrease) in prepaid expense and other assets changed year-over-year?: Syndax Pharmaceuticals's increase (decrease) in prepaid expense and other assets decreased by 30.8% year-over-year, from -$5.99M to -$7.84M.